Jungla, Inc. was a San Francisco precision-medicine informatics startup founded in 2016 by Alexander Colavin and Carlos Araya. Backed by Andreessen Horowitz (a16z) and IndieBio, it built a cloud-based Functional Modeling Platform (FMP), also described as a Molecular Evidence Platform, that combined functional genomics, computational biophysics, cellular engineering, and machine learning to produce auditable predictive models for clinical genetic and genomic variant interpretation. Jungla emerged from stealth in 2018 and was acquired by Invitae Corporation in July 2019 (approximately $59M), where its technology augmented Invitae's Sherloc variant-classification approach. The company is now defunct; its original developer surface (jungla.io) is offline and no public API, documentation, or SDKs survive. This profile is a historical record surfaced from the a16z portfolio; it carries no live developer artifacts.
Jungla is profiled on the APIs.io network. Tagged areas include Company, Precision Medicine, Genomics, Bioinformatics, and Healthcare.
aid: jungla
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source: []
generated: '2026-07-22'
method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/jungla.png
name: Jungla
description: Jungla, Inc. was a San Francisco precision-medicine informatics startup founded in 2016 by Alexander Colavin
and Carlos Araya. Backed by Andreessen Horowitz (a16z) and IndieBio, it built a cloud-based Functional Modeling Platform
(FMP), also described as a Molecular Evidence Platform, that combined functional genomics, computational biophysics, cellular
engineering, and machine learning to produce auditable predictive models for clinical genetic and genomic variant interpretation.
Jungla emerged from stealth in 2018 and was acquired by Invitae Corporation in July 2019 (approximately $59M), where its
technology augmented Invitae's Sherloc variant-classification approach. The company is now defunct; its original developer
surface (jungla.io) is offline and no public API, documentation, or SDKs survive. This profile is a historical record surfaced
from the a16z portfolio; it carries no live developer artifacts.
url: https://raw.githubusercontent.com/api-evangelist/jungla/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- a16z
- IndieBio
x-tier: stub
x-tier-reason: portfolio-lead
x-status: defunct
x-status-detail: Acquired by Invitae Corporation in July 2019; company wound down
x-acquired-by: Invitae Corporation
x-acquired-date: '2019-07-16'
x-acquired-amount-usd: 59000000
x-founded: '2016'
x-founders:
- Alexander Colavin
- Carlos Araya
x-industry: precision-medicine
x-archive-url: https://jungla.bio/
x-enrichment-note: 'Enrichment pipeline run 2026-07-19 found no live developer surface. Original domain jungla.io is dead;
jungla.bio is a static memorial page ("Jungla Inc. (2016-2019)"); jungla.com is an unrelated outdoor-kitchen product. No
OpenAPI, docs portal, SDKs, packages, MCP server, or well-known documents exist to harvest. Sources: GenomeWeb (stealth
emergence), Crunchbase, PitchBook, Invitae/Jungla acquisition press releases (PRNewswire, SEC 8-K).'
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Precision Medicine
- Genomics
- Bioinformatics
- Healthcare
- Machine-Learning
- Clinical Diagnostics
- Defunct
- Acquired
tags_raw:
- Company
- Precision Medicine
- Genomics
- Bioinformatics
- Healthcare
- Machine Learning
- Clinical Diagnostics
- Defunct
- Acquired
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
x-enrichment:
date: '2026-07-19'
status: backfilled
pass: local-v1
note: backfilled from .gitignore signal + verified work evidence
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.